Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated, platinum-resistant ...

Tointon announced last May that she carries the BRCA gene, which can significantly increase the risk of cancer.

In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal ...

ETX-19477 is a potent, selective inhibitor of poly (ADP-ribose) glycohydrolase (PARG), an enzyme that plays a role in the DNA ...

Only 23.3% of ovarian cancer patients receive BRCA testing, leading to higher treatment costs and advanced therapy lines. Non-White and low-income patients face increased financial toxicity, ...

Final overall survival (OS) results of the phase III SOLO3 trial show similar outcomes with olaparib versus non–platinum-based chemotherapy in patients with platinum-sensitive BRCA-mutated relapsed ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard ...

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. A total of 238 women with breast cancer before age 50 or ovarian cancer at any age and at ...

The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...